A detailed history of Mml Investors Services, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Mml Investors Services, LLC holds 16,028 shares of EDIT stock, worth $20,035. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,028
Previous 12,389 29.37%
Holding current value
$20,035
Previous $58,000 5.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$3.39 - $5.96 $12,336 - $21,688
3,639 Added 29.37%
16,028 $55,000
Q2 2024

Aug 14, 2024

BUY
$4.67 - $7.28 $6,290 - $9,806
1,347 Added 12.2%
12,389 $58,000
Q1 2024

May 14, 2024

SELL
$7.03 - $11.07 $8,253 - $12,996
-1,174 Reduced 9.61%
11,042 $82,000
Q4 2023

Feb 14, 2024

SELL
$6.25 - $11.11 $106,737 - $189,736
-17,078 Reduced 58.3%
12,216 $124,000
Q3 2023

Nov 14, 2023

BUY
$6.92 - $9.31 $11,570 - $15,566
1,672 Added 6.05%
29,294 $228,000
Q2 2023

Aug 14, 2023

BUY
$6.36 - $11.47 $58,238 - $105,030
9,157 Added 49.59%
27,622 $227,000
Q1 2023

May 12, 2023

BUY
$7.03 - $11.53 $7,585 - $12,440
1,079 Added 6.21%
18,465 $134,000
Q4 2022

Feb 13, 2023

BUY
$8.32 - $13.21 $32,514 - $51,624
3,908 Added 29.0%
17,386 $154,000
Q3 2022

Nov 14, 2022

BUY
$12.16 - $19.42 $163,892 - $261,742
13,478 New
13,478 $165,000
Q3 2021

Nov 15, 2021

SELL
$39.27 - $72.94 $234,834 - $436,181
-5,980 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$31.29 - $56.64 $187,114 - $338,707
5,980 New
5,980 $339,000
Q1 2021

May 14, 2021

SELL
$39.71 - $90.58 $163,764 - $373,551
-4,124 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$27.07 - $84.35 $111,636 - $347,859
4,124 New
4,124 $289,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $85.9M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Mml Investors Services, LLC Portfolio

Follow Mml Investors Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mml Investors Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mml Investors Services, LLC with notifications on news.